Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | TPMT | P51580 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30003496 | 1.00 | ALDH1A1 (0.46) | ALDH1A1HSD17B10KDM4EPTPN1TPMT | |
| SCHEMBL31643643 | 0.84 | ALDH1A1 (0.52) | ALDH1A1HSD17B10KDM4EPTPN1CA12 | |
| SCHEMBL30004188 | 0.84 | MAPT (0.43) | ALDH1A1KDM4EPTPN1CA12CA1 | |
| SCHEMBL434100 | 0.84 | MAPT (0.43) | ALDH1A1KDM4EPTPN1CA12CA1 | |
| SCHEMBL24165077 | 0.81 | HSD17B10 (0.51) | ALDH1A1HSD17B10KDM4EPTPN1TPMT | |
| SCHEMBL1323122 | 0.81 | CA12 (0.55) | ALDH1A1HSD17B10KDM4EPTPN1TPMT | |
| SCHEMBL29693892 | 0.80 | TDP1 (0.39) | ALDH1A1HSD17B10KDM4ECA12CA1 | |
| SCHEMBL1085313 | 0.80 | TDP1 (0.39) | ALDH1A1HSD17B10KDM4ECA12CA1 | |
| SCHEMBL14720094 | 0.80 | HSD17B10 (0.44) | ALDH1A1HSD17B10KDM4EPTPN1TPMT | |
| SCHEMBL31522091 | 0.80 | NR1H4 (0.38) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120842067-A | Synthesis method of 3-bromo-2-methoxy-6-methylbenzoic acid | 青岛科技大学 | 2025-10-28 | — | — | CN | disclosed |
| CN-120842067-A | Synthesis method of 3-bromo-2-methoxy-6-methylbenzoic acid | 青岛科技大学 | 2025-10-28 | — | — | CN | disclosed |
| US-20250084056-A1 | SUBSTITUTED OXOISOINDOLINYL PIPERIDINE-2,6-DIONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-13 | — | — | US | disclosed |
| WO-2025043225-A2 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 2 | GENENTECH, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20240317706-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| US-20240124459-A9 | PRPK INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2024-04-18 | — | — | US | disclosed |
| EP-4323350-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-20240051936-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-02-15 | — | — | US | disclosed |
| US-20230271966-A1 | PRPK INHIBITORS | DANA FARBER CANCER INST INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230271966-A1 | PRPK INHIBITORS | DANA FARBER CANCER INST INC (US) | 2023-08-31 | — | — | US | disclosed |
| CN-114450274-A | Indazoles and azaindazoles as LRRK2 inhibitors | 伊斯凯普生物公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2022005961-A1 | PRPK INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2022005961-A1 | PRPK INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2021007477-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2021-01-14 | — | — | WO | disclosed |
| EP-2486004-B1 | SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | ZAFGEN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| CN-105218329-B | Intermediate of liflozin analogues and preparation method of intermediate | 上海应用技术学院 | 2017-05-03 | — | — | CN | disclosed |
| WO-2017063327-A1 | NOVEL C-SPIRO-O-GLYCOSIDE COMPOUND INTERMEDIATE AND PREPARATION METHOD THEREFOR | 上海应用技术学院 | 2017-04-20 | — | — | WO | disclosed |
| EP-2486004-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen Corporation (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044506-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044506-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084056-A1 | SUBSTITUTED OXOISOINDOLINYL PIPERIDINE-2,6-DIONE COMPOUNDS | CCNA1, CCNI, CCNE1 | ALDH1A1 431/4885HSD17B10 3304/4885KDM4E 1389/4885 |
| US-20230271966-A1 | PRPK INHIBITORS | PRP4K, PRPS1, PRPF6 | ALDH1A1 1333/4885HSD17B10 1392/4885KDM4E 2930/4885 |
| US-20240317706-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | ALDH1A1 3818/4885HSD17B10 3090/4885KDM4E 2198/4885 |
| US-20240051936-A1 | ISOINDOLINONE COMPOUNDS | CRBN, CDR2, POU2F2 | ALDH1A1 1907/4885HSD17B10 2431/4885KDM4E 2644/4885 |
| US-20240124459-A9 | PRPK INHIBITORS | PRP4K, PRPS1, PRPF6 | ALDH1A1 1333/4885HSD17B10 1392/4885KDM4E 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.